MWC 2025: Intel Showcases Foundational Network Infrastructure with Xeon 6
Intel unveils silicon innovation to drive AI-powered next-generation networks.
NEWS HIGHLIGHTS
Intel® Xeon® 6 system-on-chip (SoC) with integrated AI delivers up to 2.4x more radio access network (RAN) capacity1 and up to 70% better performance-per-watt2 compared with previous generations.
Integrated AI acceleration boosts AI RAN performance by up to 3.2x over previous generations3.
Deep collaboration with 5G core solution partners accelerates the adoption of Intel® Xeon® 6 processors with Efficient-cores (E-cores) across the ecosystem.
Independent validations for 5G core workloads confirm increased rack performance, reduced power consumption and enhanced energy efficiency.
BARCELONA, Spain, March 03, 2025--(BUSINESS WIRE)--The telecommunications industry is undergoing a major transformation as AI and 5G technologies reshape networks and connectivity. While operators are eager to modernize infrastructure, challenges remain, such as high capital expenditures, security concerns and integration with legacy systems. At MWC 2025, Intel – alongside more than 50 partners and customers – will showcase groundbreaking solutions that deliver high capacity and high efficiency performance with built-in AI integration, eliminating the need for costly additional hardware and delivering optimized total cost of ownership (TCO).
"By leveraging cloud technologies and fostering close collaborations with partners, we are helping operators virtualize both 5G core and radio access networks – proving that the most demanding, mission-critical workloads can run efficiently on general-purpose silicon," said Sachin Katti, senior vice president and general manager of the Network and Edge Group at Intel Corporation. "Through our Xeon 6 processors, we are enabling the future of AI-powered network modernization."
Network Transformation and AI Acceleration
Nearly every commercial virtual radio access network deployment runs on Intel Xeon, and now the new Xeon 6 SoC, purpose-built for network and edge applications, is setting a new benchmark for performance-per-watt. By integrating AI acceleration with Intel® Advanced Vector Extensions (AVX) and Intel® Advanced Matrix Extensions (AMX), the SoC boosts AI RAN performance by up to 3.2x over previous generations4 and redefines performance without the need for discrete accelerators. Moreover, with eight integrated Ethernet ports and a total throughput of up to 200 gigabits per second (Gbps), the Intel Xeon 6 SoC provides robust connectivity.
More: Intel at MWC 2025 (Press Kit) | Intel Xeon 6 Processors (Press Kit)
This combination of optimized architecture and capacity gain means operators can dramatically reduce their server footprint, allowing them to deploy more capacity with fewer servers by enabling consolidation of multi-server open vRAN sites to a single-server footprint delivering optimized TCO. The Intel Xeon 6 SoC also includes the industry's first integrated media transcode accelerator, Intel® Media Transcode Accelerator, which delivers up to 14.25x performance-per-watt gain for video transcoding5, helping video service providers offer near-real-time experiences for live sports, gaming and auctions while significantly reducing power consumption.
Comprehensive Security for Modern Networks
As data generation surges at the network edge, security remains a critical focus. Intel Xeon 6 SoC addresses this with its leading-edge security features that enable more secure, zero-trust connections across the edge-to-cloud ecosystem.
The Impact of Intel's Ecosystem with Partners and Customers
Intel is driving the next wave of vRAN and open RAN innovation, with significant enthusiasm from leading telecom operators:
Vodafone's first OpenRAN deployments are demonstrating the competitiveness of networks built on Intel Xeon versus advanced legacy radio access networks (RAN).
AT&T is teaming up with Ericsson and Intel to build the world's most open, programmable and reliable RAN network6. This year, AT&T will begin using Intel's Xeon 6 SoC, a high-capacity, programmable virtual RAN hardware platform, to enable ongoing AI advancements through seamless software updates.
Samsung leverages Xeon 6 to enhance performance and energy efficiency, accelerating AI integration across RAN and supporting its TCO and AI objectives.
Verizon has over 40% of its nationwide 5G RAN footprint virtualized, in addition to its entire 5G core and edge. Verizon is developing the next-gen high-compute-density vRAN server, based on Intel Xeon 6, to double RAN compute capacity and enable greater energy efficiency and multitenancy, and a lower TCO.
Ericsson is industrializing Open RAN and AI RAN innovations with Xeon 6 SoC and has achieved its first Cloud RAN call on Xeon 6, powered by Dell servers.
Operators including Rakuten Mobile, Reliance Jio, SK Telecom and TELUS are advancing 5G adoption and transforming network infrastructure using Intel Xeon processors for smarter, more flexible and energy-efficient networks.
Driving a More Sustainable Future with Intel Xeon 6
Intel® Xeon® 6 processors with E-cores, launched in 2024, are experiencing widespread adoption among 5G core solution vendors and telecom operators. The addition of Intel® Infrastructure Power Manager (IPM) software enhances energy efficiency and accelerates time-to-market for customers seeking to optimize infrastructure, reduce energy consumption and minimize hardware footprints while maintaining performance.
Partners are actively adopting Xeon 6-based solutions, helping optimize energy efficiency while delivering industry-leading performance. Partner sustainability success stories include:
Ericsson's software optimizations have produced a 3.8x improvement in performance-per-watt7 versus current CoSPs' deployed configurations.
Nokia has leveraged Intel Xeon 6 processors to deliver a 60% reduction in run-time power consumption for its 5G Packet Core solution8.
Samsung's next-generation Cloud Native Core, expected in the second quarter of 2025, will feature Intel Xeon 6 processors with E-cores to achieve 3.2x better performance and density9.
Advancements in Ethernet for Modern Networks
Intel recently introduced two new families of discrete Ethernet controllers and network adapters: the E830 and E610 product lines. The Intel® Ethernet E830 family supports up to 200 Gb of bandwidth and includes precision time measurement for real-time vRAN workloads, while the Intel® Ethernet E610 family offers 10GBASE-T connectivity, ideal for power-efficient control plane networking.
Join Intel and its global ecosystem of partners and customers at MWC 2025 to explore the transformative power of the Xeon 6 family, featuring RAN breakthroughs, media and edge advancements, security innovations, enterprise services, and commercial AI PC solutions.
About Intel
Intel (Nasdaq: INTC) is an industry leader, creating world-changing technology that enables global progress and enriches lives. Inspired by Moore's Law, we continuously work to advance the design and manufacturing of semiconductors to help address our customers' greatest challenges. By embedding intelligence in the cloud, network, edge and every kind of computing device, we unleash the potential of data to transform business and society for the better. To learn more about Intel's innovations, go to newsroom.intel.com and intel.com.
1 See [7ND21] at intel.com/processor claims: Intel® Xeon® 6. Results may vary.2 See [7ND22] at intel.com/processor claims: Intel® Xeon® 6. Results may vary.3 See [7ND34] at intel.com/processor claims: Intel® Xeon® 6. Results may vary.4 See [7ND34] at intel.com/processor claims: Intel® Xeon® 6. Results may vary.5 See [7ND32] at intel.com/processor claims: Intel® Xeon® 6. Results may vary.6 AT&T to Accelerate Open and Interoperable Radio Access Networks (RAN) in the United States through new collaboration with Ericsson.7 Testing by Ericsson as of February 2025, versus platform based on 2nd Generation Intel Xeon Processors. Results may vary.8 Tested with Nokia CMM application as of February 2025, 3rd Gen Xeon 6338N vs. Xeon 6 6780E. Results may vary.9 Testing by Samsung as of February 2025, 3rd Gen Xeon 6330N vs. Xeon 6 6780E. Results may vary.
Intel does not control or audit third party data. You should consult other sources to evaluate accuracy.
Performance varies by use, configuration and other factors. Learn more on the Performance Index site.
Performance results are based on testing as of dates shown in configurations and may not reflect all publicly available updates. See backup for configuration details. No product or component can be absolutely secure.
Your costs and results may vary.
Intel technologies may require enabled hardware, software or service activation.
© Intel Corporation. Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250302532235/en/
Contacts
Krista Lopardo1-503-349-6855krista.lopardo@intel.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
BIC: Disclosure Of Trading In Own Shares For May 2025
Disclosure Of Trading In Own SharesFor May 2025 Clichy, France – June 05, 2025 In compliance with general regulation on share buy-backs, Société BIC declares below the transactions made on its own shares for May 2025: No transactions for May 2025. Contacts Brice ParisVP Investor Relations +33 6 42 87 54 Investor Bethridge ToovellVP Global Communications+1 917 821 Isabelle de Segonzac Image 7, Press Relations contact+33 6 89 87 61 39isegonzac@ Agenda All dates to be confirmed First Half 2025 Results July 30, 2025 Third Quarter 2025 Net Sales October 28, 2025 About BIC A global leader in stationery, lighters, and shavers, BIC brings simplicity and joy to everyday life. For 80 years, BIC's commitment to delivering high-quality, affordable, and trusted products has established BIC as a symbol of reliability and innovation. With a presence in over 160 countries, and over 13,000 team members worldwide, BIC's portfolio includes iconic brands and products such as BIC® 4-Color™, BodyMark®, Cello®, Cristal®, Inkbox®, BIC Kids®, Lucky™, Rocketbook®, Tattly®, Tipp-Ex®, Wite-Out®, Djeep®, EZ Load™, EZ Reach®, BIC® Flex™, Soleil®, Tangle Teezer® and more. Listed on Euronext Paris and included in the SBF120 and CAC Mid 60 indexes, BIC is also recognized for its steadfast commitments to sustainability and education. For more, visit and to see BIC's full range of products visit Follow BIC on LinkedIn, Instagram, YouTube and TikTok. Attachment BIC_Trading in own shares_MAY25

Yahoo
27 minutes ago
- Yahoo
Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Article L233-8-II of the Commercial Code Article 223-16 of the General Regulations of the AMF PARIS, June 05, 2025--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Paris:ALMKT): Listing: Euronext Growth ParisISIN code: FR0010609263, Ticker: ALMKTWebsite: Date Number of shares comprising the capital in circulation Total number of voting rights Gross Total (1) Net Total (2) May 31, 2025 74,989,997 76,077,471 76,077,471 Including 1,200,000 new shares issued during the month as part of the equity financing facility (see press releases published on July 25, 2024 and April 24, 2025). (1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights. (2) The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the shares with suspended voting rights. It is published for proper public information in accordance with the AMF recommendation of July 17, 2007. *** About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit View source version on Contacts Mauna Kea Technologies investors@ NewCap - Investor Relations Aurélie Manavarere / Thomas Grojean+33 (0)1 44 71 94 94maunakea@
Yahoo
27 minutes ago
- Yahoo
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after six months in both dose groups, although more robust with the full dose Six-month data confirm full dose selection for pivotal Phase 3 trial Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 study in children, which the Company expects to initiate in the first quarter of 2026, with the objective of extending the product label to this age group. Trial VLA1553-221's six-month results were in line with the initial data the Company reported for this trial in January 20251. A full dose (licensed IXCHIQ® formulation and presentation) elicited a more robust immune response in children aged one to eleven years at Day 15 and Day 180 post vaccination compared to a half dose. Overall, the immunological response profile was in line with what was previously observed in adults and adolescents234567. The strong immune response was confirmed in CHIKV-naïve children with a 96.5% seroresponse rate (full dose) at Day 180. VLA1553 was well tolerated in children aged one to eleven years regardless of the dose or previous CHIKV infection. No safety concerns were identified. The comparability of the VLA1553 doses tested in terms of safety and tolerability, along with the more pronounced immune response of the full dose observed for all age groups tested in children up to Day 180 post-vaccination, support the selection of the full dose for use in this population. Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, 'The six months persistence and safety data in children are aligned with the robust antibody response and safety profile we reported in adolescents after a single vaccination. Considering the significant risk chikungunya poses to individuals living in or traveling to endemic areas, it's crucial to ensure that the vaccine is accessible to people of all ages and capable of potentially offering long-term protection from a single shot. This is especially important in Low- and Middle-Income countries (LMICs) where access to vaccines is often limited.' Brazil has reported the highest number of chikungunya cases worldwide, with over one million cases between January 2019 and July 20248, followed by India with 370,000 cases during the same period. This number is rapidly increasing due to the current outbreak in the Indian states of Maharashtra and Telangana, for which the U.S. Centers for Disease Control and Prevention (CDC) issued a travel notice after identifying higher-than-expected numbers of chikungunya cases in returning travelers9. Additionally, two outbreaks are ongoing on the French islands of La Reunion and Mayotte10. About ChikungunyaChikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years11. In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since the re-emergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa, Europe and the Americas12. Between 2013 and 2023, more than 3.7 million cases were reported in the Americas13 and the economic impact is considered to be significant. The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem.14 About Phase 2 Trial VLA1553-221 VLA1553-221 is a multi-center, randomized, observer-blinded, dose response Phase 2 clinical trial in 304 healthy children aged one to eleven years. The trial is performed at three trial sites in the Dominican Republic and Honduras. The primary and secondary objectives of the trial are to evaluate the safety and immunogenicity of two different dose levels of Valneva's single-shot chikungunya vaccine. Participants were randomized 2:2:1 to receive either a full dose (licensed IXCHIQ® formulation and presentation) or a half dose of the vaccine, or an active control (Nimenrix). Additional information, including a detailed description of the trial design, eligibility criteria and investigator sites, is available at (Identifier: NCT06106581). About Valneva SEWe are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world's first and only chikungunya vaccine, as well as certain third-party from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at About CEPICEPI was launched in 2017 as an innovative partnership between public, private, philanthropic and civil organizations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI has supported the development of more than 50 vaccine candidates or platform technologies against multiple known high-risk pathogens or a future Disease X. Central to CEPI's pandemic-beating five-year plan for 2022-2026 is the '100 Days Mission' to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days. Learn more at Follow us on X (@CEPIvaccines), LinkedIn and Facebook. About Horizon EuropeHorizon Europe — #HorizonEU — is the European Union's flagship Research and Innovation programme, part of the EU-long-term Multiannual Financial Framework (MFF) with a budget of €95,5 billion to spend over a seven-year period (2021-2027). Under Horizon Europe, health research will be supported with the aim to find new ways to keep people healthy, prevent diseases, develop better diagnostics and more effective therapies, use personalised medicine approaches to improve healthcare and wellbeing, and take up innovative health technologies, such as digital ones. Valneva Investor and Media ContactsLaetitia Bachelot-FontaineVP Global Communications & European Investor RelationsM +33 (0)6 4516 Joshua Drumm, Global Investor RelationsM +001 917 815 Forward-Looking StatementsThis press release contains certain forward-looking statements relating to the business of Valneva, including with respect to use and regulatory review of existing products. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as 'could,' 'should,' 'may,' 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'aims,' 'targets,' or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results or new adverse events, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. 1 Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision - Valneva2 Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate - Valneva3 Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate - Valneva4 Lancet Paper: Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate - Valneva6 Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate - Valneva7 Lancet Paper: 12 PAHO/WHO data: Number of reported cases of chikungunya fever in the Americas (Cumulative Cases 2018-2023 and Cases per year 2013-2017). Last accessed 01 Aug 2023.14 Geographical expansion of cases of dengue and chikungunya beyond the historical areas of transmission in the Region of the Americas ( Attachment 2025_06_05_VLA1553-221_6M_Persistence_Data_PR_EN_FinalError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data